Nanobiotix SA

Nanobiotix’s early Phase II data show promising radiographic responses for JNJ‑1900 nanoradiation in stage III NSCLC, suggesting a new, safer, high‑dose radiotherapy option.

Nanobiotix SA has reported promising Phase 1 results for its NanoXray nanomedicine, NBTXR3, in patients with refractory cutaneous melanoma, demonstrating a favorable safety profile and encouraging antitumor activity when combined with immune-checkpo…